e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Studies on the mechanisms underlying airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations
L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), E. Puxeddu (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy)
Source:
International Congress 2018 – Studies on the mechanisms underlying airway disease
Session:
Studies on the mechanisms underlying airway disease
Session type:
Thematic Poster
Number:
4412
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), E. Puxeddu (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy). Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations. 4412
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Emerging inhaled bronchodilators: an update
Source: Eur Respir J 2009; 34: 757
Year: 2009
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment
Source: Eur Respir J 2015; 45: 260-262
Year: 2015
Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses
Source: International Congress 2019 – Therapeutic breakthrough Year in review
Year: 2019
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018
Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Investigating the steroids and long-acting β2-agonists combination: why do we need more?
Source: Eur Respir J 2004; 23: 501-502
Year: 2004
Inhaler preference comparing two alternative dual bronchodilator regimens
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
Novel long-acting bronchodilators
Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept